China has about 100 million people living with chronic obstructive pulmonary disease, but many remain undiagnosed or untreated, highlighting the need to strengthen screening and long-term care at the primary level, experts said on Wednesday.
The 2026 China COPD Conference was held on the 25th World COPD Day, with experts calling for greater public awareness, improved access to lung function testing and inhaled medications, and better training for community health workers.
COPD, a chronic lung disease that causes persistent breathing difficulties, affects 13.7 percent of people aged 40 and above in China. Its prevalence among people aged 70 and older is close to one-quarter, experts said at the conference.
Despite its widespread prevalence, awareness of the disease, lung function testing rates and standardized treatment rates are still lower than those for high blood pressure and diabetes, said Wang Chen, an academician of the Chinese Academy of Engineering and a respiratory disease and critical care specialist.
"Many people know about hypertension and diabetes, but COPD is relatively unfamiliar to the public," said Yang Ting, deputy head of the National Office for Chronic Respiratory Disease Prevention and Control.
China's COPD awareness rate has risen from 2.1 percent about five years ago to the low teens, but remains far short of the target of 30 percent by 2030 under the Healthy China initiative, said Yang, who is also director of the Department of Pulmonary and Critical Care Medicine at China-Japan Friendship Hospital.
Many patients mistake persistent coughing, phlegm and shortness of breath for the effects of smoking or aging, delaying diagnosis and treatment, she said.
The inclusion of COPD in China's basic public health services in September 2024 marked a milestone in disease prevention and management, giving community health centers greater opportunities to identify patients earlier, Yang said.
The program initially targeted the management of 1 million COPD patients nationwide in its first year, followed by 3 million in the second year. While implementation has made a promising start, millions of patients remain outside the screening and management system, she said.
Primary-level health facilities, however, face several obstacles, including a lack of screening expertise, insufficient lung function testing equipment, limited access to inhaled medications and inadequate clinical capabilities.
Wang highlighted the problem of improper inhaler use, saying some patients simply spray the medication into their mouths without following the prescribed technique, undermining treatment effectiveness. He said even some medical workers lack sufficient knowledge of proper inhaler use.
To address these gaps, authorities are expanding training for primary care workers through online courses, hands-on instruction, clinical guideline lectures and visits by respiratory specialists to community clinics.
The updated national essential medicines list in 2026 has also improved access to respiratory medications at primary-level facilities, allowing patients to receive prescriptions and follow-up care closer to home.
Authorities are further promoting tiered diagnosis and treatment, with community clinics managing patients with mild or stable conditions while referring severe, complicated or acute cases to higher-level hospitals.
"Early diagnosis is actually followed by early treatment," Yang said, stressing that raising public awareness and strengthening early screening are essential to reducing the disease burden.
